Diana Ranoa is a Carl R. Woese Institute for Genomic Biology Fellow. She currently works in Paul Hergenrother’s lab where she
Paul Hergenrother helps discover cancer compound now in licensing deal. Researchers affiliated with the Cancer Center at Illinois discovered a novel small molecule compound that is now the subject of a new global licensing agreement between the pharmaceutical company Bayer
eNTRyway is our web app for predicting compound accumulation in Gram-negative bacteria. It predicts the likelihood of a small-molecule to accumulate in Gram-negative bacteria. This prediction is based on the presence of a suitable ionizable nitrogen, proper shape, and flexibility.